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inhibitors was analyzed in 262 OPSCCs by immunohisto-
chemistry (IHC). Most patients (67 %) received primary 
radiotherapy with or without chemotherapy. Cox regression 
analysis was carried out to compare overall survival (OS) 
of patients with low and high TIL infiltration and expres-
sion of granzyme inhibitors.
Results HPV-positive OPSCCs were significantly more 
heavily infiltrated by TILs (p < 0.001) compared to HPV-
negative OPSCCs. A high level of CD3+ TILs was corre-
lated with a favorable outcome in the total cohort and in 
HPV-positive OPSCCs, while it reached no significance in 
HPV-negative OPSCCs. There was expression of all three 
granzyme inhibitors in OPSCCs. No differences in expres-
sion were found between HPV-positive and HPV-negative 
OPSCCs. Within the group of HPV-positive tumors, a high 
expression of SERPINB1 was associated with a signifi-
cantly worse overall survival.
Conclusion HPV-positive OPSCCs with a low count of 
CD3+ TILs or high expression of SERPINB1 have a worse 
OS, comparable with HPV-negative OPSCCs. This sug-
gests that the immune system plays an important role in the 
carcinogenesis of the virally induced oropharynx tumors.
Keywords Tumor microenvironment · Oropharynx 
squamous cell carcinoma · Human papillomavirus · 
Granzyme inhibitors · Tumor-infiltrating lymphocytes
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Abstract 
Objectives Patients with human papillomavirus (HPV)-
positive oropharyngeal squamous cell carcinomas 
(OPSCCs) have an improved prognosis compared to HPV-
negative OPSCCs. Several theories have been proposed to 
explain this relatively good prognosis. One hypothesis is a 
difference in immune response. In this study, we compared 
tumor-infiltrating CD3+, CD4+, CD8+ T-cells, and gran-
zyme inhibitors (SERPINB1, SERPINB4, and SERPINB9) 
between HPV-positive and HPV-negative tumors and the 
relation with survival.
Methods Protein expression of tumor-infiltrating lym-
phocytes (TILs) (CD3, CD4, and CD8) and granzyme 
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IHC  Immunohistochemistry
OPSCC  Oropharyngeal squamous cell carcinoma
OS  Overall survival
PORT  Postoperative radiotherapy
ROC  Receiver operating characteristic
RT  Radiotherapy
TILs  Tumor-infiltrating lymphocytes
TMA  Tissue microarray
Introduction
The causative role of the human papillomavirus (HPV), 
especially in oropharynx squamous cell carcinoma 
(OPSCC), is widely established [1]. Studies showed preva-
lence rates varying between 15 and 90 % of HPV-positive 
tumors in OPSCC worldwide and an increase is reported in 
the last two decades [2, 3]. Despite their general presenta-
tion at a more advanced stage, HPV-positive OPSCCs have 
a better survival compared to HPV-negative OPSCCs [4, 5].
The exact cause of this survival advantage is not fully 
elucidated and seems to be related to multiple factors 
such as the absence of field cancerization and wild-type 
expression of p53 and Rb [6]. Additionally, non-oro-
pharyngeal HPV-positive head and neck squamous cell 
carcinoma (HNSCC) does not show this improved out-
come compared to their HPV-negative counterparts [7]. 
This observation suggests that the behavior of a HNSCC 
induced by HPV might be influenced by the tissue micro-
environment of that specific subsite. The subepithelial tis-
sue in the oropharynx is mainly lymphoid, indicating that 
especially the immune system might harbor an important 
clue in the different behavior of HPV-positive tumors in 
the oropharynx.
For many cancers, it has become clear that in addition 
to genetic and epigenetic changes in the neoplastic cells, 
also microenvironmental factors play an important role in 
carcinogenesis and tumor progression. Cancers can survive 
the host immune response by escaping recognition and sup-
pression of the host immune system [8]. Indeed, several 
studies show an increased immune response in HPV-posi-
tive OPSCC in the primary tumor which may contribute to 
their improved treatment response [9–11].
Recognition of the important regulatory role of the 
immune system on the behavior of cancer cells has led to 
the awareness that manipulating the microenvironment 
could be used as therapeutic target. Indeed, stimulating the 
immune response against the cancer cells has been shown 
very successful in various cancer types [12, 13]. However, 
effective immunotherapy can only be achieved when poten-
tial mechanisms of the tumor to escape from recognition 
or killing by the immune system are overcome. Moreo-
ver, expression of intracellular serine protease inhibitors 
(SERPINS) by tumors could help the tumor cells to escape 
from granzyme-mediated apoptosis pathways and can 
lead to a poor response to cellular immunotherapy [8]. 
This pathway is the major mechanism via which cytotoxic 
lymphocytes eliminate virus-infected and tumor cells by 
releasing granules containing serine proteases (granzymes) 
to induce apoptosis [14, 15]. Humans express five differ-
ent granzymes ((Gr) GrA, GrB, GrK, GrH, and GrM)) and 
intracellular inhibitors for GrB, GrM, and GrH have been 
identified, being SERPINB9, SERPINB4, and SERPINB1, 
respectively [16–19].
We investigated the intratumoral immune cell response, 
as well as the expression of these intracellular granzyme 
inhibitors in OPSCC as a potential mechanism for tumor 
cell immune evasion and correlated their expression with 
clinicopathological variables such as HPV status and over-
all survival.
Materials and methods
Patient selection and clinicopathological information
Our study cohort involved 288 patients with histologically 
proven primary OPSCC curatively treated at the Univer-
sity Medical Center Utrecht, the Netherlands, between 
1997 and 2011 of which formalin fixed paraffin-embedded 
(FFPE) tissue blocks of the primary tumor were available 
in our pathology archives. The tissue blocks were incisional 
biopsies, as the treatment was mostly primary radiotherapy 
or chemoradiotherapy.
Since the tissue used was a remainder following the clin-
ical diagnostic process, no ethical approval was required 
according to Dutch national ethical guidelines (www.fed-
era.org). Anonymous or coded use of leftover tissue for 
scientific purposes is part of standard treatment agreement 
with patients in our center [20].
Tissue microarrays were constructed as described previ-
ously [21]. Briefly, hematoxylin–eosin-stained slides were 
examined and revised by a dedicated head and neck pathol-
ogist (S. M. Willems) to mark representative tumor regions. 
Four tissue microarrays (TMA) were constructed using a 
fully automated tissue microarray instrument (TMA Grand 
Master, Beecher Instruments). From each tumor block, 
three cores with a diameter of 0.6 mm were punched out 
and placed in a recipient paraffin block. Areas including 
necrosis were avoided. In addition, normal oropharynx 
mucosa obtained from patients with neck metastasis from 
an unknown primary tumor was incorporated in each block 
as a control among the different TMAs. Nowadays, TMAs 
are accepted as a fast and accurate approach for the evalu-
ation of immunohistochemical stainings in large groups 
[22].
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From all included OPSCCs, patient characteristics, clini-
cal TNM classification (based on palpation, ultrasound-
guided fine-needle aspiration, MRI or CT, and classified in 
a multidisciplinary panel) based on the AJCC TNM clas-
sification of malignant tumors 7th edition and survival 
data were extracted from medical records. HPV status was 
determined for all tumors by a combination of p16 immu-
nohistochemistry and linear array, as described earlier [21]. 
Adequate DNA for HPV testing and enough percentage 
tumor cells (>30 %) for constructing a TMA was available 
for 262 cases of the initial 288 OPSCC cohort (91 %).
Immunohistochemistry
Immunohistochemical evaluation of tumor-infiltrating lym-
phocytes, GrB, and the three granzyme inhibitors (SER-
PINB1, SERPINB4, and SERPINB9) was performed on 
4 µm paraffin TMA slides. Sections were heated at 60 °C 
overnight. All tissue sections were deparaffinized with 
xylene and rehydrated in decreasing ethanol dilutions. 
Endogenous peroxidase activity was blocked for 15 min 
in a 0.3 % hydrogen peroxidase phosphate-citrate buffer 
(pH 5.8) followed by antigen retrieval. For CD3+, CD4+, 
CD8+, granzyme B, and SERPINB1, IHC staining was 
performed using an automated immunostainer (Benchmark 
Ultra, Ventana, Roche). All other stainings were performed 
manually. After antigen retrieval by boiling the sections in 
EDTA buffer pH 9.0 or citrate buffer pH 6.0 for 20 min, 
sections were cooled within the buffers for 30 min followed 
by incubation with the primary antibodies for 60 min. The 
used antibodies, antigen retrieval, and appropriate dilu-
tions are summarized in Table 1. For the detection of the 
primary antibodies, a poly-HRP anti-mouse, rabbit, rat 
(ready to use: Brightvision, DPVO-HRP, immunologic), 
or in case of SERPINB4, the Novolink kit (Leica) was 
used according to manufacturer’s protocol. Between steps, 
slides were washed three times with PBS. Slides were then 
developed with diaminobenzidine for 10 min followed by 
counterstaining with hematoxylin, dehydration in alco-
hol and mounting. Finally, the sections were coverslipped. 
Appropriate negative and positive controls were used in all 
stainings.
Evaluation of immunohistochemical staining
Scoring of TMA cores was performed mutually by a dedi-
cated head and neck pathologist (S. M. Willems) and a 
researcher (P. M. W. van Kempen), both blinded to clinical 
characteristics of the patients. A core was excluded when 
>95 % of the core contained no tissue or when the core 
contained <5 % tumor tissue. Discordance was resolved 
by discussion and consonance. Patients were only included 
in the analyses if one or more tumor cores were avail-
able. For CD3+, CD4+, and CD8+, the number of posi-
tively stained lymphocytes infiltrating the tumor tissue was 
counted. For SERPINB1 and SERPINB4, the percentages 
of nuclear or cytoplasmic stained tumor cells were scored. 
For SERPINB4, staining intensity was scored as well and 
evaluated as absent (0), weak (1), moderate (2), and strong 
(4). SERPINB9 was scored as positive (staining in more 
than 10 % of tumor cells) or negative as used in previous 
studies [23]. We investigated the expression of SERPINS 
in neoplastic epithelial cells, although SERPINS are also 
expressed in other cell types, e.g., lymphocytes and fibro-
blasts where they exhibit specific functions [24].
When more than one core was available for one case, 
the mean number (CD3+, CD4+, CD8+) or the mean 
percentage (SERPINB1, SERPINB4) was calculated. For 
SERPINB4, a H-score was calculated by multiplying the 
mean percentage of SERPINB4 staining with the maxi-
mum staining intensity. For all these proteins, an optimized 
cutoff point with regard to overall survival was identified 
using ROC curves. For CD3+, the optimal cutoff value was 
150, and for CD4+ and CD8+, it was 100. For SERPINB1 
and SERPINB4, it both was 50 %, and using the H-score 
for SERPINB4, the threshold was identified at 150. The 
activity of cytotoxic tumor-infiltrating lymphocytes was 
examined by GrB expression. Per tumor core, the num-
ber of GrB-positive cells were counted and divided by the 
number of cytotoxic lymphocytes.
Table 1  Overview of used 
antibodies
Antigen retrieval Clone Company Dilution Positive control
P16 EDTA 16P07 Neomarkers 1:200 Tonsil
CD3+ EDTA A452 Dako 1:100 Tonsil
CD4+ EDTA SP35 CellMarque 1:50 Tonsil
CD8+ Citrate M7103 Dako 1:50 Tonsil
SERPINB1 EDTA Ab47731 Abcam 1:800 Pancreas tumor
SERPINB4 Citrate 10C12 Santa cruz 1:50 Skin
SERPINB9 Citrate Clone 17 Ref. [44] 1:400 Tonsil
Granzyme B Citrate GB7 Ref. [45] 1:250 Tonsil
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Statistical analyses
SPSS IBM, version 22.0, was used for all analyses. Dif-
ferences in patient characteristics between HPV-positive 
and HPV-negative OPSCCs were calculated using the 
Pearson’s chi-squared test for categorical variables and 
the student’s t test for normally distributed continuous 
variables. The Mann–Whitney U test was used to assess 
differences in the expression of CD3+, CD4+, CD8+, 
SERPINB1, and SERPINB4 between the HPV-positive 
and HPV-negative OPSCCs as these continuous variables 
were non-normally distributed. Correlations were ana-
lyzed using Pearson correlation. Overall survival (OS) 
was used as outcome endpoint and defined as the time 
between date of first tumor positive biopsy and death. 
Censored patients were confirmed alive at time of censor-
ing. Thus, there was no loss to follow-up. Survival rates 
were plotted according to the Kaplan–Meier method, 
and associations were analyzed using the log-rank test. 
Effect modification and confounding were investigated. 
Multivariate analyses were performed using the Cox pro-
portional hazard model in a stepwise-backward selection 
procedure including the variables that were significant 
in univariate analysis. Receiver operating characteris-
tic (ROC) curves analyses were used to determine cutoff 
points for protein expression and survival. Statistical sig-
nificance was set at p < 0.05.
Results
Patients’ characteristics
The study included 262 OPSCC patients with a mean age 
of 59 at primary diagnosis. Overall, 17 % of the OPSCCs 
were HPV-positive and 83 % were HPV-negative. Patient 
and tumor characteristics are depicted in Table 2. In line with 
the literature, patients with HPV-negative tumors had higher 
T-stages compared to patients with HPV-positive tumors, 
but there were fewer cases of nodal metastases. With regard 
to smoking and alcohol abuse, patients with HPV-positive 
tumors used significant less alcohol. There was no significant 
difference between the groups considering smoking. Cis-
platinum-based chemoradiotherapy (CCRT) was the main 
treatment of patients (Table 2). CCRT was administered to 
patients below 70 years of age, if tumors were functionally 
or technically inoperable (T3–T4 tumors) and if there were 
no further contra-indications to undergo this treatment.
HPV‑status and tumor infiltration by immune cells
Due to insufficient tissue, a few cases could not be evalu-
ated for CD3+, CD4+, or CD8+ staining (Table 2). The 
number of intratumoral CD3+, CD4+, and CD8+ cells 
was assessed and compared between HPV-positive and 
HPV-negative OPSCCs (Fig. 1a). The mean number of 
intratumor CD3+, CD4+, and CD8+ cells was signifi-
cantly higher in HPV-positive tumors. The number of 
tumor-infiltrating CD3+, CD4+, and CD8+ positive cells 
was dichotomized (CD3+ with a cutoff value of 150; 
CD8+ and CD4+ with a cutoff value of 100) and com-
pared between HPV-positive and HPV-negative tumors. A 
high number (>150) of tumor-infiltrating CD3+ cells was 
observed in 28 of 214 (13 %) HPV-negative tumors com-
pared to 25 of 43 (58 %) HPV-positive tumors (p < 0.001). 
Furthermore, a high number intratumor CD4+ and CD8+ 
positive cells (>100) was found in 41 of 213 (19 %) and 31 
of 208 (15 %) HPV-negative tumors versus 21 of 43 (49 %) 
and 23 of 39 (59 %) HPV-positive tumors. These differ-
ences were significant (p < 0.001).
Expression of granzymes inhibitors
In normal tissue of the oropharyngeal region SERPINB9, 
SERPINB1, and SERPINB4, expression was absent. For 
SERPINB9, SERPINB1, and SERPINB4, we mainly 
observed a cytoplasmic staining with sometimes nuclear 
staining as well (Fig. 1b). The proportion of patients 
with positive and negative SERPIN staining is depicted 
in Table 2. Even though SERPIN expression was in all 
cases lower in HPV-positive tumors than in HPV-negative 
tumors, none of these differences reached statistical sig-
nificance. SERPINB9 expression could be scored in 235 
OPSCCs (90 %). The expression level of SERPINB9 was 
heterogeneous and positive in 28 (12 %) of 235 evaluable 
cases. There was no significant difference in SERPINB9 
expression between HPV-positive and HPV-negative 
tumors. SERPINB1 and SERPINB4 expression could be 
scored in 242 (92 %) and 243 (93 %) of the cases, respec-
tively. Using a cutoff value of 50 %, 71 tumors of the 242 
(29 %) showed a high expression of SERPBINB1 in the 
total cohort. The HPV-positive OPSCC showed a high 
expression of SERPINB1 in 25 % (10 of 40) compared to 
30 % (61 of 202) of HPV-negative, though this difference 
was not significant (p = 0.639). SERPINB4 staining inten-
sity, as well as the percentage of SERPINB4 positive tumor 
cells, was compared between HPV-positive and HPV-neg-
ative OPSCC. The SERPINB4 intensity, dichotomized as 
absent (0)/weak (1) versus moderate (2)/strong (3), was 
observed as high (moderate/strong) in 18 of 39 (46 %) 
of HPV-positive OPSCC compared to 120 of 204 (59 %) 
HPV-negative tumors (p = 0.564). Using a cutoff value 
of 50 %, 20 of 39 (51 %) HPV-positive compared to 124 
of 204 (61 %) HPV-negative tumors showed a high SER-
PINB4 expression (p = 0.353). Results are summarized in 
Table 2.
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We correlated expression of intratumoral CD3+, CD4+, 
and CD8+ to expression of the granzyme inhibitors. There 
was no significant correlation between expression of TIL’s 
and granzyme inhibitors. GrB expression was evaluated 
to determine the activity of cytotoxic tumor-infiltrating 
lymphocytes. Tumors that showed SERPINB9 expression 
(>10 %) contained a significant higher percentage of gran-
zyme B-positive cytotoxic T lymphocytes (CTLs) (mean 
granzyme B-positive CTLs 23 vs. 38 % in SERPINB9 pos-
itive tumors).
Effect of tumor infiltration by immune cells 
and granzyme inhibitors on survival
Univariate analyses using Kaplan–Meier curves were per-
formed to evaluate factors potentially associated with OS. 
The analyses were performed in the total cohort, as well 
as stratified for patients with HPV-positive and HPV-neg-
ative tumors The median follow-up was 35 months for all 
patients (interquartile range [IQR]: 15.8–67.0). Of the total 
cohort of 274 patients, 151 (55 %) patients had died at the 
end of follow-up.
Prognostic factors included in the univariate analysis 
were as follows: age, gender, tumor size (cT1-2 vs. cT3-4), 
smoking, alcohol use, nodal stage (cN0 vs. cN+), number 
of intratumor CD3+, CD8+, and CD4+ cells, SERPINB9 
staining (positive vs. negative), SERPINB1 staining (high 
vs. low expression), and SERPINB4 staining (H-score high 
vs. low expression). In the total group, HPV-positivity, 
small tumor size (T1–T2), no lymph node metastasis, high 
number of CD3+ and CD8+ intratumor cells, and a low 
expression of SERPINB1 in tumor cells were all individu-
ally significant associated with an improved OS (Table 3, 
Fig. 2). The Cox proportional hazard regression model 
Table 2  Patient and tumor characteristics of 262 OPSCC by HPV 
status
Patient or tumor 
characteristics
HPV-positive (%) HPV-negative (%) p value
No. of cases 44 (17) 218 (83) –
Age
 Average (range) 58 (35–80) 59 (39–83) 0.225
Sex
 Male 34 (77) 148 (68)
 Female 10 (23) 70 (32) 0.292
Smoking historya
 Never or quit 
>1 year
25 (57) 94 (43)
 Yes or quit <1 year 19 (43) 122 (56) 0.148
Alcohol useb
 Never or quit 
>1 year
26 (59) 60 (28)
 Yes or quit <1 year 18 (41) 154 (71) <0.001
Overall AJCC stagec
 Stage I-II 5 (11) 42 (19)
 Stage III-IV 39 (89) 175 (80) 0.297
AJCC tumor sizec
 T1–2 24 (55) 85 (39)
 T3–4 19 (43) 133 (61) 0.041
AJCC nodal staged
 N0 5 (11) 86 (39)
 N1-3 39 (89) 130 (60) <0.001
Treatment
 Surgery only 1 (2) 14 (6)
 Surgery + PORT 9 (20) 57 (26)
 Surgery + PORCT 1 (2) 4 (2)
 Primary RT 13 (30) 56 (26)
 Primary CCRT 20 (46) 87 (40) 0.738
Second primary tumorsa
 No 43 (98) 199 (91)
 Yes 1 (2) 17 (8) 0.314
Intratumor CD3+ cells
 0–150 18 (42) 186 (87)
 >150 25 (58) 28 (13) <0.001
Intratumor CD4+ cells
 0–100 21 (49) 172 (81)
 >100 22 (51) 41 (19) <0.001
Intratumor CD8+ cells
 0–100 16 (41) 177 (85)
 >100 23 (59) 31 (15) <0.001
SERPINB9 expression
 0–10 % 36 (97) 189 (95)
 >10 % 1 (3) 9 (5) 0.947
SERPINB1 expression
 0–49 % 30 (75) 141 (70)
 >50 % 10 (25) 61 (30) 0.639
HPV Human papillomavirus, PORT postoperative radiotherapy, RT 
Radiotherapy, CCRT cisplatinum based chemoradiotherapy, AJCC 
American Joint Committee on Cancer. Due to insufficient tissue a few 
cases could not be evaluated for CD3+ (5), CD4+ (6), CD8+ (15), 
SERPINB1 (20), SERPINB4 (19) and SERPINB9 (27) staining
a  2 missing; b 4 missing values; c 1 missing; d 2 missing
Table 2  continued
Patient or tumor 
characteristics
HPV-positive (%) HPV-negative (%) p value
No. of cases 44 (17) 218 (83) –
SERPINB4 expression
 0–49 % 19 (49) 80 (39)
 >50 % 20 (51) 124 (61) 0.353
SERPINB4 intensity
 Absent/weak 18 (46) 84 (41)
 Moderate/strong 21 (54) 120 (59) 0.689
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showed that tumor size (T1–T2), nodal stage (N0), HPV 
positivity, and a high number of intratumor CD3+ cells 
were independent prognostic factors for an improved OS 
(Table 4).  
In HPV-negative patients, tumor size and nodal stage 
were correlated with OS in univariate analysis. Neither 
number of infiltration of T-cells nor SERPINB1 expression 
was of significant importance. In HPV-positive tumors, a 
high number of intratumoral CD3+ cells, low expression of 
SERPINB1, and younger age were associated with a signif-
icant better OS (Table 3; Fig. 2). As the group of HPV-pos-
itive patients was rather small and only 10 deaths occurred 
in this subgroup, multivariate analysis was not possible. In 
HPV-negative patients, multivariate analysis showed that 
a high T- or N-stage were independently associated with a 
worse OS, while CD3+ cell influx was not (Table 4).
Fig. 1  a Staining patterns of CD3+, CD4+, and CD8+. Example of 
a 0.6 mm TMA core with low expression on the left side (A) and high 
expression on the right side for CD3+ (B) (magnification 10× and 
magnification 20×). The same for CD4+ (C, D) and CD8+ (E, F). b 
Staining patterns of granzyme B, SERPINB1, SERPINB4, and SER-
PINB9. Example of a 0.6 mm TMA core with low expression on the 
left side compared to high expression on the right side for granzyme 
B (A, B), SERPINB1 (C, D), SERPINB4 (E, F), and SERPINB9 (G, 
H) (magnification 10× and magnification 20×)
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Discussion
Previous studies showed that the immune system is involved 
in the process of carcinogenesis of HNSCC and elevated 
levels of tumor-infiltrating lymphocytes (TILs) are associ-
ated with an improved survival [9, 25]. Considering the 
poor survival rates, HNSCC patients may therefore benefit 
from additional immunotherapy in the future. In this study, 
Table 3  Univariate models for overall survival
Significant values are shown in bold
HPV Human papillomavirus, OPSCC oropharyngeal squamous cell carcinoma, CI confidence interval, CCRT radiotherapy with or without adju-
vant chemotherapy
Overall survival Total cohort HPV-positive OPSCC HPV-negative OPSCC
Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value
Gender (male vs. female) 0.85 (0.59–1.23) 0.387 0.34 (0.04–2.68) 0.305 0.86 (0.59–1.26) 0.434
Age (>60 vs. younger) 1.08 (0.78–1.51) 0.644 3.97 (1.02–15.4) 0.046 0.93 (0.66–1.31) 0.670
Tumor size (T3–4 vs. T1–2) 2.10 (1.45–3.00) <0.001 3.19 (0.82–12.4) 0.093 1.90 (1.32–2.74) <0.001
Nodal stage (N+ vs. N0) 1.82 (1.26–2.62) <0.001 1.14 (0.14–9.00) 0.902 2.55 (1.73–3.77) <0.001
Smoking (current/quit vs. never ever) 0.78 (0.56–1.09) 0.148 0.77 (0.53–1.11) 0.159 0.79 (0.56–1.11) 0.176
Alcohol use (current/quit vs. never ever) 1.00 (0.71–1.43) 0.97 1.53 (0.44–5.29) 0.501 0.77 (0.53–1.11) 0.768
Number of CD3+ cells (>150 vs. 0–149) 0.36 (0.21–0.61) <0.001 0.29 (0.09–0.95) 0.042 0.61 (0.37–1.03) 0.065
Number of CD4+ cells (>100 vs. 0–99) 0.66 (0.43–1.00) 0.051 0.58 (0.16–2.05) 0.393 0.84 (0.54–1.32) 0.456
Number of CD8+ cells (>100 vs. 0–99) 0.37 (0.22–0.62) <0.001 0.31 (0.08–1.24) 0.100 0.57 (0.32–1.01) 0.054
SERPINB1 (>50 % vs. 0–49 %) 1.60 (1.11–2.31) 0.012 4.58 (1.22–17.1) 0.024 1.37 (0.93–2.00) 0.110
SERPINB4 (H-score) (>150 vs. 0–149) 1.12 (0.79–1.58) 0.527 1.92 (0.56–6.63) 0.304 1.05 (0.73–1.50) 0.812
SERPINB9 (>10 % vs. 0–9 %) 0.84 (0.47–1.50) 0.563 0.05 (0.00–7397) 0.637 0.75 (0.42–1.34) 0.330
HPV (positive vs. negative) 0.28 (0.15–0.54) <0.001 – – – –
Treatment (CCRT vs. surgery) 1.41 (0.98–2.01) 0.062 34.67 (0.11–11372) 0.230 1.38 (0.96–1.99) 0.081
Fig. 2  Kaplan–Meier curves 
for OPSCC overall survival. 
Kaplan–Meier curves of OS. 
a For high levels (>150) of 
intratumoral CD3+ cells versus 
low levels in the total cohort of 
OPSCC. Log-rank p < 0.001, 
hazard ratio = 0.36 (0.21–0.61), 
p < 0.001. b For HPV-positive 
tumors. Log-rank p = 0.029, 
hazard ratio = 0.29 (0.09–0.95), 
p = 0.042 c For HPV-negative 
tumors. Log-rank p = 0.060, 
hazard ratio = 0.61 (0.37–1.03), 
p = 0.065. d Kaplan–Meier 
OS curve for SERPINB1 
expression stratified for HPV 
status. It shows that the OS of 
HPV-positive tumors with a 
high SERPINB1 expression is 
comparable to HPV-negative 
patients
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we evaluated the amount of CD3+, CD4+, CD8+ TILs, 
and expression of granzyme inhibitors SERPINB1, SER-
PINB4, and SERPINB9 in relation to HPV-status and sur-
vival in OPSCC. In our study, HPV-positive tumors showed 
to have a significantly higher number of CD3+, CD4+, and 
CD8+ TILs. A high number of CD3+ TILs correlated with 
improved survival, independent of HPV status. In addition, 
we show for the first time that OPSCCs express granzyme 
inhibitors (SERPINB1, SERPINB4, and SERPINB9) to 
evade granzyme-induced cytotoxicity. Their expression 
was not different between HPV-positive and HPV-negative 
tumors. However, a high SERPINB1 expression identified 
a subgroup of HPV-positive tumors with a poor survival, 
which is comparable to HPV-negative tumors.
In OPSCC, HPV status is a prognostic biomarker as HPV-
positive tumors have a better long-term survival compared to 
HPV-negative OPSCC [1]. Moreover, HPV-positive OPSCC 
represents a distinct entity with different tumor biology 
reflected on genetic and epigenetic levels [26, 27]. We hypoth-
esized that the immune response and expression of granzyme 
inhibitors may also differ between HPV-positive and HPV-
negative tumors. In our study, the immune profiles of HPV-
positive and HPV-negative OPSCC were distinct, notable for 
differences in levels of CD3+, CD8+, and CD4+ TILs. This 
suggests that viral proteins released by HPV-positive tumors 
might be presented in MHC class I and II molecules on the 
surface and elicit a strong immune response after recognition 
by CD4+ and CD8+ T-cells. This pro-immunogenic effect of 
HPV triggers an anti-tumorigenic immune response, which 
might partly explain the improved survival in this group. 
These findings are in line with the previous studies, although 
not in all studies the differences were statistically signifi-
cant [9–11, 28–34]. This could be explained by the variation 
in HPV detection methods, difference in used antibodies for 
assessing of intratumoral lymphocytes and used cutoff values.
As HPV-positive patients have an improved survival com-
pared to those with HPV-negative OPSCC, it could be that 
less intensive treatment regimens in HPV-positive tumors 
could achieve similar efficacy with less side effects. There-
fore, several clinical trials are currently investigating dif-
ferent ways to de-escalate treatment and still receive local 
control [35]. However, several studies showed that not all 
HPV-positive OPSCC have an excellent survival [4, 36]. Gil-
lison et al. [36] showed that heavy smoking patients with a 
HPV-positive tumor have reduced survival, almost compa-
rable to patients with HPV-negative tumors. Additionally, 
Ward et al. [9] developed a prognostic model suggesting 
that patients with HPV-positive tumors with low levels of 
tumor-infiltrating lymphocytes have similar survival rates to 
HPV-negatives. This is in line with the findings in our cohort 
showing that elevated levels of CD3+ cells are an independ-
ent predictor for improved survival of OPSCC comparable in 
strength to HPV status as prognosticator. A stratified analysis 
in HPV-positive and HPV-negative patients showed that an 
increased influx of CD3+ cells in HPV-positive patients is 
significant associated with an improved survival. In contrast, 
in HPV-negative patients, this association reached no signifi-
cance. These results suggest that the immune system plays a 
more important role in the clinical behavior of HPV-positive 
OPSCC than in HPV-negative OPSCC.
SERPIN family members play pivotal roles in the inhi-
bition of serine proteases in blood coagulation, mental dis-
eases, and innate immune responses [37]. Studies with knock 
out of SERPINB1 in mice showed a significant role for SER-
PINB1 in protecting lung antimicrobial proteins from prote-
olysis during microbe infection and its regulatory role in sus-
taining the balance of neutrophil reserve [38, 39]. Increasing 
evidence shows that granzyme H participates in the defense 
of inflammation and SERPINB1 is identified as a possible 
inhibitor [19]. This study identified that a high expression 
of SERPINB1 is associated with a worse prognosis in HPV-
positive patients and could be a mechanism of the tumor to 
escape from recognition or killing by the immune system. 
A possible explanation is that the immunogenic response 
is higher in HPV-positive OPSCC, and therefore, the effect 
of granzyme inhibition is more effective in HPV-positive 
tumors. Alternatively, Tseng et al. [40] showed that SER-
PINB1 might have a role in promoting motility in oral cancer 
cells and increasing invasiveness. This indicates a correlation 
with tumor metastases and therefore a worse prognosis.
In selecting patients properly for immunotherapy, it is 
important to account for the presence of suppressive mech-
anisms of immune system. The granule exocytosis pathway 
is the major mechanism via which cytotoxic lymphocytes, 
Table 4  Multivariate model for overall survival in total cohort and for HPV-negative OPSCC
HPV Human papillomavirus, OPSCC oropharyngeal squamous cell carcinoma, CI confidence interval
Overall survival Total cohort OPSCC HPV-negative OPSCC
Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value
Tumor size (T3-4 vs. T1-2) 1.73 (1.17–2.58) 0.007 1.79 (1.23–2.60) 0.003
Nodal stage (N+ vs. N0) 2.58 (1.70–3.91) <0.001 2.37 (1.60–3.51) <0.001
HPV (positive vs. negative) 0.35 (0.16–0.74) 0.006
Number of CD3+ cells (>150 vs. 0–149) 0.39 (0.21–0.73) 0.003
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including natural killer (NK) cells and cytotoxic T-lym-
phocytes, counteract virus-infected cells and tumor tissue. 
The principal mechanism of killing in this pathway is by 
the release of granules containing the pore-forming pro-
tein perforin and a family of structurally homologues ser-
ine proteases known as granzymes into the immunological 
synapse. Pore formation induced by perforin facilitates the 
introduction of granzymes into the cell. In the cell, they 
can induce apoptosis by the cleavage of intracellular sub-
strates [14, 41]. Humans express five different granzymes: 
granzyme A, B, H, K, and M [16]. All these granzymes 
can induce cell death, although each granzyme induces a 
unique pathway that only overlaps partially. The balance 
between activation and inhibition of the proteolytic cas-
cade must be tightly controlled to avoid self-damage by, 
for example, intracellular leakage of granzymes. Addition-
ally, tumor and virus-infected cells use strategies to evade 
granzyme induced cell death. It has been well established 
that granzyme B activity is controlled by SERPINB9 [42]. 
Recently, two other granzyme inhibitors were identified. 
SERPINB1 has been identified as a granzyme H inhibitor 
and SERPINB4 as a granzyme M inhibitor [17, 19]. There-
fore, we assessed the expression of these three granzyme 
inhibitors. Multiple studies show that expression of SER-
PINB9 in melanomas is correlated with worse survival and 
poor response to immunotherapy [43]. For HNSCC, the 
expression of granzyme inhibitors has not been studied yet. 
In this study, we show for the first time that SERPINB9, 
SERPINB1, and SERPINB4 are not expressed in normal 
tissue, but expression can be acquired in OPSCC. There 
was no difference in expression of the studied SERPINS 
between HPV-positive and HPV-negative tumors. No corre-
lation was found between the expression of SERPINS and 
the number of TILs. The observation of expression of gran-
zyme inhibitors in OPSCC is important as it may affect the 
success rate of immunotherapy in OPSCC.
The results of study should be viewed within the con-
straints of several limitations. First, TMA’s were used 
for the evaluation of the IHC stainings. Although TMA 
is accepted nowadays as a fast and accurate approach for 
the evaluation of IHC stainings in large groups, it must 
be denoted that it could introduce possible bias due to the 
high heterogeneity of HNSCC. Second, overexpression of 
SERPINB1 in HPV-positive OPSCC showed a significant 
association with worse survival, but the low number of 
patients and events (N = 10) in the HPV-positive group did 
not allow for multivariate analysis. Therefore, our results 
should be validated in a cohort with higher numbers of 
HPV-positive patients, and analyses should be stratified for 
therapy.
In conclusion, it is plausible that the immune system 
plays a more important role in carcinogenesis of virally 
induced oropharynx tumors. Consequently, HPV-positive 
patients with a high expression of SERPINB1 or low 
invasion of CD3+ cells should receive additional therapy 
instead of treatment de-escalation.
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